newsfilter.io

Health Information Services — industry outlook

  • Period: 2026-10-19 to 2026-11-09
  • Events: 18
  • Generated: 2026-11-09T07:30:00.003Z

Revenue and Margin Guidance Revisions

Multiple companies revised FY2026 guidance upward, signaling strong execution and demand resilience across diagnostics, virtual care, and health IT segments. Quest Diagnostics (CRA) raised FY2026 revenue guidance to $12.065 billion–$12.105 billion (9.3%–9.7% growth) and Adjusted EPS to $11.25–$11.35, citing robust volume trends and a 30%+ growth rate in Consumer Health. Teladoc Health (TDOC) increased FY2026 revenue guidance to $2.39B–$2.44B and Adjusted EBITDA to $277M–$303M, driven by better-than-expected insurance adoption at BetterHelp. Hinge Health (HNGE) lifted FY2026 revenue to $879M–$881M and operating income to $266M–$288M, reflecting "insatiable" demand. Doximity (DOCS) raised FY27 revenue to $678M–$683M and Adjusted EBITDA to $317M–$325M, supported by AI search ramp and health system adoption. Progyny (PGNY) raised FY2026 revenue to $1.365B–$1.385B and Adjusted EBITDA to $235M–$240M. Conversely, HealthStream (HSTM) raised FY2026 revenue to $331M–$333M despite acknowledging near-term margin pressure from AWS migration. GE HealthCare (GEHC) raised FY2026 organic revenue growth to ~4%, Adjusted EBIT Margin to 15.5%–15.7%, and Adjusted EPS to $4.95–$5.05, attributing improvements to volume, price, and reduced tariffs. Solventum (SOLV) raised FY2026 organic sales growth to the high end of 2.5%–3% and EPS to $7.20–$7.30, while Tempus (TEM) raised FY2026 revenue to $1.60B–$1.605B.

Market Growth Drivers: Volume, Specialization, and Demographics

Organic volume growth remains a primary industry engine, with Quest Diagnostics (CRA) citing sustained 5% organic volume growth in Q3 expected to continue, and GE Healthcare (GEHC) noting capital budgets remain a top priority for CFOs with no procedure pullbacks. The market is seeing distinct growth in specialized areas: Quest (CRA) projects Consumer Health growth exceeding 30%, driven by "dense rems"; GEHC (GEHC) expects Pharmaceutical Diagnostics (PDX) to grow in the low double digits following the Sophie Biosciences acquisition, with a target of a $500 million run rate for Forcado by FY2028. Hinge Health (HNGE) identifies 88% of market lives as untapped for MSK care, with strong penetration in the SMB segment. Progyny (PGNY) attributes demand to the 1-in-5 infertility prevalence rate and employer cost control needs. In virtual care, Teladoc (TDOC) highlights the shift toward hybrid care models following the Teledyne Health acquisition, while Amwell (AMWL) notes health plans shifting from "access" to "outcomes" due to projected 8–11% healthcare cost increases in 2027. Doximity (DOCS) reports a $14 billion US pharma paid search market opportunity, with 81% of surveyed pharma marketers planning to increase spend on their platform.

Strategic Shifts to AI, Bundling, and Outcomes-Based Models

A dominant theme is the transition from point-solution software to integrated platforms and outcomes-based pricing. Hinge Health (HNGE) is launching GI and Migraine programs in Summer 2027 and early 2027 respectively, moving toward an integrated care platform. Doximity (DOCS) is launching AI Search as a separate advertising product in FY28, utilizing DoseCheck for safety. Waystar (WAY) is shifting to performance-based pricing for its Iodine integration, bundling Clinical Documentation Integrity with pre-bill anomaly detection. Teladoc (TDOC) is pivoting BetterHelp from cash-pay to an in-network insurance model, targeting a $200M annualized run rate by end-2027. HealthStream (HSTM) is reorganizing its sales force to lead with enterprise suites (Competency, Compliance) rather than point solutions, expected to drive larger contract values in 2027. Amwell (AMWL) is adopting outcome-based pricing where revenue scales with utilization and savings, moving away from pure SaaS fees. GEHC (GEHC) is leveraging AI to secure "favored nation" status for supply chain components amidst the "vortex effect" of data center growth on memory chips.

Regulatory Headwinds: PAMA, Tariffs, and IRA

Legislative and regulatory pressures present the most significant variance in company outlooks. Quest Diagnostics (CRA) estimates the PAMA "Results Act" could delay rate cuts, with a potential ~1% revenue impact in 2027 if enacted as is, and a cumulative impact of <1.3% from 2027–2029. They advocate for reform to correct CMS data weighting. In contrast, Progyny (PGNY) and Tempus (TEM) explicitly state they expect minimal to no PAMA impact on their specific test portfolios (hereditary cancer and liquid biopsy), respectively. GE Healthcare (GEHC) and Solventum (SOLV) identify Section 232 tariffs as the "biggest swing item" for 2027 margins, though GEHC expects 75 basis points in FX tailwinds and has secured multi-year chip agreements to mitigate supply chain inflation. BrightSpring (BTSG) faces a $200 million annualized impact from the IRA on its Home and Community Pharmacy segment in 2026, expected to persist into 2027 but offset by operational efficiencies. Sophia Genetics (SOPH) continues to manage FX headwinds from USD strength and ongoing UK litigation, while Teladoc (TDOC) notes no specific tariff impacts but highlights broader regulatory changes.

M&A, Capital Allocation, and Operational Efficiency

M&A activity is expected to increase, particularly for BrightSpring (BTSG), which anticipates larger transactions ($20M+ EBITDA) and views 2027 as a "very positive year" for volume. Solventum (SOLV) is executing a separation of its Health Information Systems (HIS) unit, with a target to complete the spin/sale process and realize $400 million in shareholder returns, while noting a potential 400 basis points of annualized margin dilution post-separation. Tempus (TEM) is closing its acquisition of Personalis, expecting to absorb short-term burn but unlock significant growth in the MRD business by late 2027. Doximity (DOCS) and HealthStream (HSTM) are utilizing cash on hand for opportunistic buybacks, with Doximity maintaining a debt-free balance sheet and HealthStream having $115.2M in cash. Solventum (SOLV) and GEHC (GEHC) are both deploying capital to fund organic growth, with GEHC increasing its dividend by 14%. Quest Diagnostics (CRA) is investing in its "Invigorate" program to generate 3% in annual cost savings to offset wage inflation of $120M+.